ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
About ContraFect Corporation
- NASDAQ: $CFRX
- Notified: $7.00
- 07:31 EDT
